EE200100136A - Use of an acetylcholine esterase inhibitor and an antipsychotic agent in the manufacture of a medicament for the treatment of cognitive and psychotic disorders, and a pharmaceutical composition containing these agents - Google Patents
Use of an acetylcholine esterase inhibitor and an antipsychotic agent in the manufacture of a medicament for the treatment of cognitive and psychotic disorders, and a pharmaceutical composition containing these agentsInfo
- Publication number
- EE200100136A EE200100136A EEP200100136A EEP200100136A EE200100136A EE 200100136 A EE200100136 A EE 200100136A EE P200100136 A EEP200100136 A EE P200100136A EE P200100136 A EEP200100136 A EE P200100136A EE 200100136 A EE200100136 A EE 200100136A
- Authority
- EE
- Estonia
- Prior art keywords
- cognitive
- medicament
- agents
- manufacture
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP98203454 | 1998-10-16 | ||
| PCT/EP1999/007804 WO2000023057A2 (en) | 1998-10-16 | 1999-10-12 | Atypical antiphsychotic in combination with acetylcholinesterase inhibitor for improving cognition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EE200100136A true EE200100136A (en) | 2002-06-17 |
Family
ID=8234219
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EEP200100136A EE200100136A (en) | 1998-10-16 | 1999-10-12 | Use of an acetylcholine esterase inhibitor and an antipsychotic agent in the manufacture of a medicament for the treatment of cognitive and psychotic disorders, and a pharmaceutical composition containing these agents |
Country Status (20)
| Country | Link |
|---|---|
| EP (1) | EP1121131A2 (en) |
| JP (1) | JP2002527469A (en) |
| KR (1) | KR20010072878A (en) |
| CN (1) | CN1367697A (en) |
| AU (1) | AU6472799A (en) |
| BG (1) | BG105302A (en) |
| BR (1) | BR9914419A (en) |
| CA (1) | CA2345767A1 (en) |
| EE (1) | EE200100136A (en) |
| HK (1) | HK1039745A1 (en) |
| HR (1) | HRP20010262A2 (en) |
| HU (1) | HUP0103781A3 (en) |
| ID (1) | ID28441A (en) |
| IL (1) | IL142588A0 (en) |
| NO (1) | NO20011403D0 (en) |
| PL (1) | PL348107A1 (en) |
| SK (1) | SK4592001A3 (en) |
| TR (1) | TR200101082T2 (en) |
| WO (1) | WO2000023057A2 (en) |
| ZA (1) | ZA200103081B (en) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0102841D0 (en) * | 2001-02-05 | 2001-03-21 | Novartis Ag | Organic compounds |
| AU2006201188B2 (en) * | 2001-02-05 | 2007-11-15 | Novartis Ag | New use of iloperidone |
| DE60238780D1 (en) | 2001-10-30 | 2011-02-10 | Novartis Ag | DEPOT FORMULATIONS OF ILOPERIDONE AND A STAR-TERM POLYMER |
| GB0216416D0 (en) | 2002-07-15 | 2002-08-21 | Novartis Ag | Organic compounds |
| WO2004084905A2 (en) * | 2003-03-24 | 2004-10-07 | University Of Florida | Use of 5-ht2c receptor activity affecting compounds for treating idiopathic hyperhidrosis and associated conditions |
| TW200501962A (en) * | 2003-04-01 | 2005-01-16 | Novartis Ag | Use of carbamazepine derivatives for the treatment of agitation in dementia patients |
| WO2006065233A1 (en) * | 2004-12-10 | 2006-06-22 | Abbott Laboratories | Fused bicycloheterocycle substituted quinuclidine derivatives |
| WO2005065645A2 (en) * | 2003-12-31 | 2005-07-21 | Actavis Group Hf | Donepezil formulations |
| EP2089383B1 (en) | 2006-11-09 | 2015-09-16 | Probiodrug AG | 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases |
| US9126987B2 (en) | 2006-11-30 | 2015-09-08 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
| JP5930573B2 (en) | 2007-03-01 | 2016-06-15 | プロビオドルグ エージー | New use of glutaminyl cyclase inhibitors |
| DK2142514T3 (en) | 2007-04-18 | 2015-03-23 | Probiodrug Ag | Thiourea derivatives as glutaminyl cyclase inhibitors |
| MX2007008642A (en) * | 2007-07-16 | 2009-02-25 | World Trade Imp Export Wtie Ag | Pharmaceutical composition comprising the combination of a benzisoxazolic derived agent and a reversible inhibiting agent of the cholinesterase enzyme prescribed for the control and treatment of psychotic disorders and dementias. |
| CA2789014C (en) | 2010-02-09 | 2019-01-15 | Michela Gallagher | Methods and compositions for improving cognitive function |
| JP6026284B2 (en) | 2010-03-03 | 2016-11-16 | プロビオドルグ エージー | Inhibitors of glutaminyl cyclase |
| US8269019B2 (en) | 2010-03-10 | 2012-09-18 | Probiodrug Ag | Inhibitors |
| EP2560953B1 (en) | 2010-04-21 | 2016-01-06 | Probiodrug AG | Inhibitors of glutaminyl cyclase |
| US8530670B2 (en) | 2011-03-16 | 2013-09-10 | Probiodrug Ag | Inhibitors |
| US10154988B2 (en) | 2012-11-14 | 2018-12-18 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
| ES2881081T3 (en) | 2013-03-15 | 2021-11-26 | Agenebio Inc | Procedures and compositions to improve cognitive function |
| EP3827820A1 (en) | 2013-03-15 | 2021-06-02 | The Johns Hopkins University | Brivaracetam for improving cognitive function |
| CN107810002B (en) | 2015-05-22 | 2021-01-05 | 艾吉因生物股份有限公司 | Extended release pharmaceutical compositions of levetiracetam |
| ES2812698T3 (en) | 2017-09-29 | 2021-03-18 | Probiodrug Ag | Glutaminyl cyclase inhibitors |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5336675A (en) * | 1991-05-14 | 1994-08-09 | Ernir Snorrason | Method of treating mania in humans |
| EP0515301A3 (en) * | 1991-05-14 | 1993-06-16 | Ernir Snorrason | Improvements in benzodiazepine treatment by cholinesterterase inhibitors |
| JP4640888B2 (en) * | 1997-08-11 | 2011-03-02 | ザ ユニヴァーシティー オブ サウス フロリダ | Nicotine antagonists for neuropsychiatric disorders |
| DK1073432T3 (en) * | 1998-04-14 | 2007-12-17 | Gen Hospital Corp | Use of D serine or D alanine for the treatment of schizophrenia |
-
1999
- 1999-10-12 EP EP99952580A patent/EP1121131A2/en not_active Withdrawn
- 1999-10-12 HU HU0103781A patent/HUP0103781A3/en unknown
- 1999-10-12 CA CA002345767A patent/CA2345767A1/en not_active Abandoned
- 1999-10-12 EE EEP200100136A patent/EE200100136A/en unknown
- 1999-10-12 TR TR2001/01082T patent/TR200101082T2/en unknown
- 1999-10-12 BR BR9914419-0A patent/BR9914419A/en not_active IP Right Cessation
- 1999-10-12 WO PCT/EP1999/007804 patent/WO2000023057A2/en not_active Application Discontinuation
- 1999-10-12 CN CN99812184A patent/CN1367697A/en active Pending
- 1999-10-12 SK SK459-2001A patent/SK4592001A3/en unknown
- 1999-10-12 JP JP2000576832A patent/JP2002527469A/en not_active Withdrawn
- 1999-10-12 ID IDW20010828A patent/ID28441A/en unknown
- 1999-10-12 PL PL99348107A patent/PL348107A1/en unknown
- 1999-10-12 KR KR1020017002286A patent/KR20010072878A/en not_active Application Discontinuation
- 1999-10-12 IL IL14258899A patent/IL142588A0/en unknown
- 1999-10-12 AU AU64727/99A patent/AU6472799A/en not_active Abandoned
-
2001
- 2001-03-01 BG BG105302A patent/BG105302A/en unknown
- 2001-03-20 NO NO20011403A patent/NO20011403D0/en not_active Application Discontinuation
- 2001-04-10 HR HR20010262A patent/HRP20010262A2/en not_active Application Discontinuation
- 2001-04-12 ZA ZA200103081A patent/ZA200103081B/en unknown
-
2002
- 2002-01-10 HK HK02100158.6A patent/HK1039745A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA200103081B (en) | 2002-07-12 |
| CA2345767A1 (en) | 2000-04-27 |
| BG105302A (en) | 2001-11-30 |
| CN1367697A (en) | 2002-09-04 |
| IL142588A0 (en) | 2002-03-10 |
| AU6472799A (en) | 2000-05-08 |
| SK4592001A3 (en) | 2001-12-03 |
| JP2002527469A (en) | 2002-08-27 |
| HK1039745A1 (en) | 2002-05-10 |
| PL348107A1 (en) | 2002-05-06 |
| WO2000023057A2 (en) | 2000-04-27 |
| KR20010072878A (en) | 2001-07-31 |
| HUP0103781A2 (en) | 2002-03-28 |
| ID28441A (en) | 2001-05-24 |
| EP1121131A2 (en) | 2001-08-08 |
| HRP20010262A2 (en) | 2002-06-30 |
| NO20011403L (en) | 2001-03-20 |
| TR200101082T2 (en) | 2001-09-21 |
| BR9914419A (en) | 2001-06-26 |
| WO2000023057A3 (en) | 2000-07-27 |
| HUP0103781A3 (en) | 2003-09-29 |
| NO20011403D0 (en) | 2001-03-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EE200100136A (en) | Use of an acetylcholine esterase inhibitor and an antipsychotic agent in the manufacture of a medicament for the treatment of cognitive and psychotic disorders, and a pharmaceutical composition containing these agents | |
| EE200100495A (en) | Carbohydrate-substituted 1,4-benzothiazepine-1,1-dioxide derivatives, process for their preparation, use of the compounds and medicament containing them | |
| HUP0103856A3 (en) | Pharmaceutical composition for the treatment of acute disorders | |
| AR028426A1 (en) | A PHARMACEUTICAL COMPOSITION AND PROCEDURE FOR THE TREATMENT OF COGNITIVE DYSFUNSION DISEASES IN A MAMMER | |
| NO20006630L (en) | Pharmaceutical composition for the treatment of diabetes | |
| HUP0302476A3 (en) | Use of acetylcholinesterase inhibitors and gabaainverse agonists for the treatment of cognitive disorders and for preparation of pharmaceutical compositins | |
| IL147217A0 (en) | New spirooxindole derivatives and pharmaceutical compositions containing the same for treatment of pain | |
| PT956858E (en) | PHARMACEUTICAL COMPOSITIONS CONTAINING LACTOBACILS FOR THE TREATMENT OF VAGINAL INFECTIONS | |
| EE200200274A (en) | Use of a pyrrolidine acetamide derivative in the manufacture of a medicament for the treatment of disorders of the central nervous system, and a pharmaceutical composition | |
| PL341343A1 (en) | Composition for treating respiratory diseases and dermatoses containing at least one leucotriene antagonist and at least one antihistaminic agent | |
| DE69836008D1 (en) | COMPOSITION AND TREATMENT AGENT | |
| HUP0104709A2 (en) | Use of erythropoietin or erythropoietin derivatives for the manufacture of a medicament for treatment of cerebral ischaemia | |
| EE200100179A (en) | Pharmaceutical agents for the treatment of Parkinson's disease, ADHD and microvascular adenomas | |
| EE200300167A (en) | Amidoalkylpiperidine and Piperazine Derivatives, Pharmaceutical Composition Containing Them, and Use of Compounds for the Treatment of Nervous System Disorders | |
| EP1146879A4 (en) | Methods and compositions for prevention and treatment of restenosis with non-steroidal anti-inflammatory drugs | |
| CA2284551A1 (en) | New therapeutic combinations of mirtazapine and antipsychotic agents, for the treatment or prophylaxis of psychotic disorders | |
| HUP9802795A3 (en) | Pharmaceutical compositions containing beta-adrenergic agent and anorectic agent for the treatment of corpulence | |
| EP1177798A3 (en) | A pharmaceutical composition for the treatment of attention deficit hyperactivity disorder(ADHD) comprising a nicotine receptor partial agonist and anti-ADHD agent | |
| HUP9902405A3 (en) | Pharmaceutical compositions containing a serotonin antagonist for the treatment of the common cold or allergic rhinitis | |
| NO20011695D0 (en) | Long-release pharmaceutical composition and method of releasing pharmaceutically active agent | |
| NZ513650A (en) | Pharmaceutical composition for the treatment of urinary incontinence, motion sickness and vertigo | |
| EE04493B1 (en) | Cyclopentene derivatives, a pharmaceutical composition containing them and their use as a medicament for the treatment of motilin receptor-related disorders in humans | |
| HUP0301830A3 (en) | Pharmaceutical composition containing a combination of fbpase inhibitors and antidiabetic agents useful for the treatment of diabetes | |
| IL150289A0 (en) | Drug combination for the treatment of depression and related disorders comprising mirtazapine | |
| EE04914B1 (en) | Eletriptan Hydrobromide Monohydrate, Its Use and Process for its Preparation, and Pharmaceutical Composition Containing Eletriptan Hydrobromide Monohydrate |